Model Mole Information

ModelMole is an AI drug discovery company developing an autonomous, infrastructure-agnostic platform for molecular design and optimisation. Founded in 2023 and headquartered in the United Kingdom, the company combines physics-based computational chemistry with state-of-the-art machine learning to discover novel therapeutic candidates that lie beyond the reach of conventional AI approaches. The platform is built around a proprietary swarm AI system that orchestrates multiple models in parallel, cross-referencing predictions to quantify confidence and automatically filling data gaps using molecular dynamics, quantum mechanical, and docking calculations. An automatic active learning loop iteratively improves predictions with every problem solved, enabling the platform to "look into the dark" — exploring sparse regions of chemical space where traditional ML models fail. ModelMole is fully autonomous and infrastructure-agnostic, designed to run on environments ranging from enterprise compute clusters to a single workstation. The platform supports the full discovery pipeline — drug design, delivery, formulation, stability, and optimisation — and is currently used by clients in oncology, antimicrobial development, regenerative medicine, and cosmetics. The company's research is published in leading peer-reviewed journals including the Royal Society of Chemistry's PCCP, the Journal of Physical Chemistry Letters, Cell, and Angewandte Chemie. Active programmes include targeted radiotheranostics for oncology, antimicrobial peptides and peptide-drug conjugates, transcription regulator discovery, and collagen repair peptides for soft tissue regeneration. ModelMole is supported by UK Research and Innovation (UKRI) and works with academic partners including the Royal Society of Chemistry. Model Mole Ltd is registered in England and Wales (No. 14909542).